Decreased brain dopamine cell numbers in human cocaine users

Psychiatry Research

Volumn 168, Issue 3, 2009, Pages 173-180

  Little, Karley Y ^a,b   Ramssen, Eric ^a   Welchko, Ryan ^a   Volberg, Vitaly ^a   Roland, Courtney J ^a   Cassin, Bader ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cocaine; Cocaine dependence; Dopamine; Dopamine transporter; Neurotoxicity; Parkinson's Disease

Indexed keywords

COCAINE; DOPAMINE; MELANIN; TYROSINE 3 MONOOXYGENASE;

ADULT; ANHEDONIA; ARTICLE; BRAIN BIOPSY; CELL COUNT; CELL INFILTRATION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC NERVE CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; MALE; MESENCEPHALON; MICROGLIA; NERVE INJURY; NEUROTOXICITY; PATHOPHYSIOLOGY; PHAGOCYTE; PRIORITY JOURNAL; STAINING;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL COUNT; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; NEURONS; PLANT LECTINS; PROTEIN BINDING; TRITIUM; TYROSINE 3-MONOOXYGENASE; YOUNG ADULT;

EID: 67650457127     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.10.034     Document Type: Article

References (71)

1. Beskow K., Gottfries C.G., Roos B.E., and Winblad B. Determination of monoamine and monoamine metabolites in the human brain: postmortem studies in a group of suicides and in a control group. Acta Psychiatrica Scandinavia 53 (1976) 7-20
2. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Experimental Neurology 155 2 (1999) 268-273
3. Borght V., Klibourn M., Desmond T., Kuhl D., and Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. European Journal of Pharmacology 194 (1995) 577-583
4. Callahan B.T., Cord B.J., Yuan J., McCann U.D., and Ricaurte G.A. Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity. Journal of Neurochemistry 77 5 (2001) 1348-1362
5. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., and Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447 7148 (2007) 1081-1086
6. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., and O'Brien C.P. Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry 156 1 (1999) 11-18
7. Cornelius J.R., Salloum I.M., Thase M.E., Haskett R.F., Daley D.C., Jones-Barlock A., Upsher C., and Perel J.M. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacology Bulletin 34 1 (1998) 117-121
8. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., and Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochemical & Biophysical Research Communications 290 (2002) 1545-1550
9. Dietrich J., Mangeol A., Revel M., Burgun C., Aunis D., and Zwiller J. Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. Neuropharmacology 48 (2005) 965-974
10. Domingo P., and Martinez E. Parkinsonism associated with long-term cocaine abuse. Archives of Internal Medicine 157 2 (1997) 24
11. Elsworth J.D., Taylor J.R., Sladek Jr. J.R., Collier T.J., Redmond Jr. D.E., and Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95 2 (2000) 399-408
12. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., and Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97 1 (2000) 99-112
13. Frey K.A., Koeppe R.A., and Kilbourn M.R. Imaging the vesicular monoaminetransporter. Advances in Neurology 86 (2000) 237-247
14. German D.C., Nelson E., Liang C.L., Speciale S.G., Sinton C.M., and Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 4 (1996) 299-312
15. Gibb W.R. Neuropathology of the substantia nigra. European Neurology 31 Suppl 1 (1991) 48-59
16. Gibb W.R., and Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. Journal of Neurology, Neurosurgery, & Psychiatry 54 5 (1991) 388-396
17. Goldstein R.Z., Tomasi D., Rajaram S., Cottone L.A., Zhang L., Maloney T., Telang F., Alia-Klein N., and Volkow N.D. Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction. Neuroscience 144 4 (2007) 1153-1159
18. Graham D. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molecular Pharmacology 14 (1978) 633-643
19. Gundersen H.J.G., Bendtsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., and Vesterby A. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Acta Pathologica, Microbiologica et Immunologica Scandinavica 96 (1988) 379-394
20. Hald A., Van Beek J., and Latharius J. Inflammation in Parkinson's Disease: causative or epiphenomenal?. Sub-cellular Biochemistry 42 (2007) 249-279
21. Hardy J.A., Wester P., Backstrom I., Gottfries H., Oreland L., and Stenstrom A. The regional distribution of dopamine and serotonin uptake and transmitters concentrations in the human brain. Neurochemistry International 10 (1987) 445-450
22. Harvey D.C., Lacan G., and Melega W.P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Experimental Brain Research 133 3 (2000) 349-358
23. Hattori A., Luo Y., Umegaki H., Munoz J., and Roth G.S. Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport 9 (1998) 2569-2572
24. Hitri A., Little K.Y., and Ellinwood E.H. Effect of cocaine on dopamine transporter receptors depends on routes of chronic cocaine administration. Neuropsychopharmacology 14 (1996) 205-210
25. Hogan K.A., Staa R.G., and Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. Journal of Neurochemistry 74 5 (2000) 2217-2220
26. Hortnagl H., Schlogl E., Sperk G., and Hornykiewicz O. The topographical distribution of the monoaminergic innnervation in the basal ganglia of the human brain. Progressive Brain Research 542 (1983) 300-306
27. Hsu S.M., Raine L., and Fanger H. Comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. American Journal of Clinical Pathology 75 (1981) 734-738
28. Kampman K.M., Volpicelli J.R., Alterman A., Cornish J., Weinrieb R., Epperson L., Sparkman T., and O'Brien C.P. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug & Alcohol Dependence 41 1 (1996) 25-33
29. Kilbourn M.R., Kuszpit K., and Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35 4 (2000) 250-255
30. Kitao Y., Matsuyama T., Takaro K., Tabato Y., Yoshimoto T., Momai T., Yamatodani A., Ogawa S., and Hori O. Does ORP150/HSP12A protect dopaminergic neurons against MPTP/MPP(+)-induced neurotoxicity?. Antioxidants & Redox Signaling 9 5 (2007) 589-595
31. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. Journal of Neuroscience 22 20 (2002) 8951-8960
32. Letchworth S.R., Nader M.A., Smith H.R., Friedman D.P., and Porrino L.J. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. Journal of Neuroscience 21 8 (2001) 2799-2807
33. Liberatore G.T., Finkelstein D.I., Wong J.Y., Horne M.K., Porritt M.J., Donnan G.A., and Howells D.W. Sprouting of dopaminergic axons after striatal injury: confirmation by markers not dependent on dopamine metabolism. Experimental Neurology 159 (1999) 565-573
34. 125I]RTI-55 binding sites in cocaine-abusing humans. Progressive Neuro-Psychopharmacology & Biological Psychiatry 22 (1998) 455-466
35. Little K.Y., Elmer L.W., Zhong H., and Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Molecular Pharmacology 61 (2002) 436-445
36. 3H]WIN 35428 binding sites in human striatum. Brain Research 628 (1993) 17-25
37. Little K.Y., Krolewski D.M., Zhang L., and Cassin B.J. Loss of striatal vesicular monoamine transporter (VMAT2) in human cocaine users. American Journal of Psychiatry 160 (2003) 47-55
38. Little K.Y., McLaughlin D., Zhang L., McFinton P.R., Dalack G.W., Cook E.H., Cassin B.J., and Watson S.J. Brain dopamine transporter mRNA and binding sites in cocaine users: a post mortem study. Archives of General Psychiatry 55 (1998) 793-799
39. Little K.Y., Zhang L., Desmond T., Frey K.A., Dalack G.W., and Cassin B.J. Striatal dopaminergic alterations in human cocaine users. American Journal of Psychiatry 156 (1999) 238-245
40. Malison R.T., Best S.E., Van Dyck C.H., McCance E.F., Wallace E.A., Laruelle M., Baldwin R.M., Seibyl J.P., Price L.H., Kosten T.R., and Innis R.B. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. American Journal of Psychiatry 155 6 (1998) 832-834
41. Mannoji H., Yeger H., and Becker E. A specific histochemical marker (lectin Ricinus communis agglutinin-1) for normal human microglia, and application to routine histopathology. Acta Neuropatholigica (Berlin) 71 (1986) 341-343
42. Martinez D., Narendran R., Foltin R.W., Slifstein R., Hwang D., Broft A., Huang Y., Cooper T.B., Fischman M.W., Kleber H.D., and Laruelle M. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. American Journal of Psychiatry 164 (2007) 622-629
43. Mash D.C., Pablo J., Ouyang Q., Hearn W.L., and Izenwasser S. Dopamine transport function is elevated in cocaine users. Journal of Neurochemistry 81 2 (2002) 292-300
44. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., and Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. Journal of Neuroscience 18 20 (1998) 8417-8422
45. McRitchie D.A., Cartwright H.R., and Halliday G.M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Experimental Neurology 144 (1997) 202-213
46. Melikian H.E., and Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. Journal of Neuroscience 19 (1999) 7699-7710
47. Mirza B., Hardberg H., Thomsen P., and Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95 2 (2000) 425-432
48. Mody C.K., Miller B.L., McIntyre H.B., Cobb S.K., and Goldberg M.A. Neurologic complications of cocaine abuse. Neurology 38 (1988) 1189-1193
49. Moszczynska A., Fitzmaurice P., Ang L., Kalasinsky K.S., Schmunk G.A., Peretti F.J., Aiken S.S., Wickham D.J., and Kish S.J. Why is Parkinsonism not a feature of human methamphetamine users?. Brain 127 (2004) 363-370
50. Mulvaney F.D., Alterman A.I., Boardman C.R., and Kampman K.M. Cocaine abstinence symptomatology and treatment attrition. Journal of Substance Abuse Treatment 16 2 (1999) 129-135
51. Ouyang Q., Pablo J., and Mash D.C. Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. Neuroreport 16 13 (2005) 1489-1493
52. Parish C.L., Finkelstein D.I., Drago J., Borrelli E., and Horne M.K. The role of dopamine receptors in regulating the size of axonal arbors. Journal of Neuroscience 21 14 (2001) 5147-5157
53. Paxinos G., and Huang X.F. Atlas of the Human Brainstem (1995), Academic Press, San Diego
54. Ryan L.J., Martone M., Linder J., and Groves P.M. Cocaine, in contrast to d-amphetamine, does not cause axonal terminal degeneration in neostriatum an agranular frontal cortex of Long-Evans rats. Life Science 43 (1988) 1403-1409
55. Schiffer W.K., Volkow N.D., Fowler J.S., Alexoff D.L., Logan J., and Dewey S.L. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59 4 (2006) 243-251
56. Schmidt C., Ritter J., Sonsalla P., Hanson G., and Gibb J. Role of dopamine in the neurotoxic effects of methamphetamine. Journal of Pharmacology and Experimental Therapeutics 233 (1985) 539-544
57. 2High dopamine receptors. Synapse 60 (2006) 319-346
58. Sofuoglu M., and Kosten T.R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs 11 1 (2006) 91-98
59. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., and Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Research 738 1 (1996) 172-175
60. Staley J.K., Hearn L., Ruttenber J., Wetli C.V., and Mash D.C. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. Journal of Pharmacology and Experimental Therapeutics 271 (1994) 1678-1685
61. Staley J.K., Talbot J.Z., Ciliax B.J., Miller G.W., Levey A.I., Kung M.P., Kung H.F., and Mash D.C. Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Research 747 2 (1997) 219-229
62. Stark A.K., and Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Research 318 (2004) 81-92
63. Van Domburg P.H., and ten Donkelaar H.J. The human substantia nigra and ventral tegmental area: a neuroanatomical study with notes on aging. Advanced Anatomical Embryo Cell Biology 121 (1991) 1-132
64. Volkow N.D., Fowler J.S., Wang G.J., Hitzemann R., Logan J., Schlyer D.J., Dewey S.L., and Wolf A.P. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14 (1993) 169-177
65. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Hitzemann R., Chen A.D., Dewey S.L., and Papppas N. Decreased striatal responsiveness in detoxified cocaine-dependent subjects. Nature 386 (1997) 830-833
66. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemann R., Gatley S.J., MacGregor R.R., and Wolf A.P. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14 (1996) 159-168
67. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., and Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Medicine 2 6 (1996) 699-703
68. Wilson J.M., Levey A.I., Bergeron C., Kalasinsky K., Ang L., Peretti F., Adams V.I., Smialek J., Anderson W.R., Shannak K., Deck J., Niznik H.B., and Kish S.J. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Annals of Neurology 40 (1996) 428-439
69. Wilson J.M., and Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chromic cocaine self-administration in the rat. Journal of Neuroscience 16 10 (1996) 3507-3510
70. Yeh S.Y., and DeSouza E.B. Lack of neurochemical evidence for neurotoxic effects of repeated cocaine administration in rats on brain monoamine neurons. Drug and Alcohol Dependence 27 (1991) 41-61
71. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., and Barzalai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-a possible novel pathogenetic mechanism in Parkinson's disease. Neuroscience Letters 170 (1994) 136-140